June 14, 2011 (Dallas, Texas) — Hospitals need to pick up the pace in prescribing anticoagulation therapy for prophylaxis against deep vein thrombosis (DVT) and pulmonary embolism (PE), and do a ...
The US Food and Drug Administration (FDA) has approved dabigatran etexilate (Pradaxa) oral pellets for the treatment of venous thromboembolism (VTE) in children aged 3 months to less than 12 years.
Ingelheim/Germany, 14 September 2007 – Boehringer Ingelheim today announced the publication of the RE-NOVATE study in the September 15 issue of The Lancet1. The results demonstrate that the oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback